Global Search | Novartis

Showing 1240 results

Press release / Jan 27, 2015

Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses

Net sales grew in FY 2014, with strong core[1] margin expansion Net sales increased 1% (+3% cc[1])[2] to USD 58.0 billion in FY (Q4: -2%, +4% cc) Operating income grew 1% (+7% cc) to USD 10.7…
Press release / Jan 27, 2015

Novartis a enregistré en 2014 une forte augmentation de ses ventes, sa marge et progrès de son pipeline; la transformation du portefeuille concentrera l'entreprise sur ses principales activités

Hausse du chiffre d'affaires net en 2014, avec une forte augmentation de la marge core[1] Hausse du chiffre d'affaires net de 1% (+3% tcc[1])[2] à USD 58,0 milliards en 2014 (-2%, +4% tcc au T4)…
Press release / Jan 23, 2015

Novartis Bexsero® vaccine approved by FDA for the prevention of meningitis B, a leading cause of bacterial meningitis in the US

With today's approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide Bexsero's two-dose regimen offers a flexible…
Press release / Jan 23, 2015

Novartis drug Jakavi® recommended by CHMP for EU approval to treat adults with rare blood cancer polycythemia vera

Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack[1] Clinical data show Jakavi® (…
Press release / Jan 21, 2015

Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patients

Offering a new treatment option for patients, Cosentyx is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A[1],[2] Phase III data demonstrated…
Press release / Jan 19, 2015

Novartis Cosentyx(TM) is the first IL-17 inhibitor to receive EU approval for first-line treatment of moderate-to-severe psoriasis patients

Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects[1]; all other…
Press release / Jan 12, 2015

Novartis Pharmaceuticals announces a joint investment company with Qualcomm, leading innovation in digital medicines for physicians and patients

Novartis establishing a joint investment company with Qualcomm Ventures, the venture investment group of Qualcomm Incorporated, of up to USD 100 million to support early stage companies with…
Press release / Jan 08, 2015

Novartis announces robust Phase III results for QVA149 and NVA237 and submits regulatory applications to US FDA

Pivotal Phase III results for QVA149 and NVA237 met their primary endpoints and significantly improved lung function in COPD patients[1-5] US trials for QVA149 demonstrated significant…
Press release / Jan 07, 2015

Sandoz biosimilar filgrastim recommended for approval by FDA Oncologic Drugs Advisory Committee

Oncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the US Biosimilar filgrastim recommended to be approved for use in all requested…
Press release / Jan 07, 2015

Novartis collaborates with Intellia Therapeutics and Caribou Biosciences to explore making medicines and drug discovery tools with CRISPR genome editing technology

Collaborations give Novartis access to novel CRISPR technology platforms for the discovery and development of new medicines Intellia Therapeutics collaboration to explore therapeutic options for…